| Methods |
|
| Participants |
Country: Latvia Setting: university hospital outpatient dialysis unit Diagnostic criteria: no detailed information Number: treatment group (27); control group (26) Mean age ± SD: 49.8 ± 10.1 years Sex (M/F): 26/27 Comorbidities: hypophosphataemia, non‐diabetic |
| Interventions |
Treatment group
Discontinued the use of calcium acetate for the first 2 weeks, then received 30 to 40 g Ca‐bread, which containing 2.5% of elemental calcium (by weight) 3 times a day for the next 8 weeks, then consumed the Ca‐bread between their main meals for the next 2 weeks, and returned to the initial diet for the last 2 weeks
Control group
Received calcium acetate (Calcium Nephro 700, Medice, Germany) as the principal phosphate binder (5 to 7 capsules of 700 mg calcium acetate or 886 to 1,244 mg elemental calcium was consumed with the patient's main meals on a thrice daily basis)
|
| Outcomes |
Mean serum phosphorus (mmol/L) Mean serum calcium (mmol/L) Mean calcium × phosphate product Total alkaline phosphatase activity (U/L) iPTH (pmol/L) |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not reported |
| Allocation concealment (selection bias) |
Unclear risk |
Not reported |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Not reported |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Not reported |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No missing data |
| Selective reporting (reporting bias) |
Unclear risk |
Insufficient information to permit judgement |
| Other bias |
Unclear risk |
Insufficient information to permit judgement |
